8 pages, 976 KiB  
Article
Pyuria Is Associated with Dysbiosis of the Urinary Microbiota in Type 2 Diabetes Patients Receiving Sodium–Glucose Cotransporter 2 Inhibitors
by Hsueh-Ju Lin, Han-Ni Chuang, Pei-Pei Jhan, Han-Yu Ye, I-Te Lee, Tzu-Hung Hsiao and Po-Yu Liu
Microbiol. Res. 2023, 14(1), 34-41; https://doi.org/10.3390/microbiolres14010003 - 27 Dec 2022
Cited by 2 | Viewed by 2977
Abstract
Treating type 2 diabetes (T2D) patients with sodium–glucose cotransporter 2 (SGLT2) inhibitors may be associated with an increased risk of urinary tract infections (UTIs), such as diabetes-induced asymptomatic bacteriuria. Pyuria—a condition wherein leukocytes are detected in the urine—is a predictor of UTIs. The [...] Read more.
Treating type 2 diabetes (T2D) patients with sodium–glucose cotransporter 2 (SGLT2) inhibitors may be associated with an increased risk of urinary tract infections (UTIs), such as diabetes-induced asymptomatic bacteriuria. Pyuria—a condition wherein leukocytes are detected in the urine—is a predictor of UTIs. The aim of this study was to examine the urinary microbiome of Taiwanese T2D patients, with or without pyuria, undergoing SGLT2 treatment. We recruited seven T2D patients, recorded their clinical and biochemical characteristics, and collected their urine samples for 16S metagenomic sequencing. The primary outcomes were the diversity of urinary microbiota and the relative abundance of different species. We found that the microbiome of the pyuria group was significantly less diverse than the non-pyuria group (0.24 ± 0.04 vs. 2.21 ± 0.28, p = 0.002), while the number of operational taxonomic units did not differ significantly (763.5 ± 78.67 and 747 ± 141.3, p = 0.92). Escherichia-Shigella spp. dominated the microbiome of the pyuria group (97.4%–99.4%), and these patients tended to have more comorbidities. In conclusion, pyuria is associated with urinary microbiota dysbiosis in T2D patients being treated with SGLT2 inhibitors. Full article
Show Figures

Figure 1

13 pages, 1621 KiB  
Article
Serum PCR Diagnosis of Brucella melitensis Infection in Rev. 1 Vaccinated Sheep
by Shubham Mathur, Svetlana Bardenstein, Daniel Cohen and Menachem Banai
Microbiol. Res. 2023, 14(1), 21-33; https://doi.org/10.3390/microbiolres14010002 - 23 Dec 2022
Cited by 1 | Viewed by 3135
Abstract
Serological diagnosis provides a robust and effective approach to monitoring and controlling small ruminant brucellosis. Brucella melitensis Rev. 1 is a live vaccine strain used in prophylactic vaccination against small ruminant brucellosis. Because the vaccine strain shares identical serological antigens with the corresponding field [...] Read more.
Serological diagnosis provides a robust and effective approach to monitoring and controlling small ruminant brucellosis. Brucella melitensis Rev. 1 is a live vaccine strain used in prophylactic vaccination against small ruminant brucellosis. Because the vaccine strain shares identical serological antigens with the corresponding field strains, differentiating infected from vaccinated animals (DIVA) serological responses hamper surveillance campaigns and interventions that involve vaccination. We have developed a serum PCR-based approach in which we amplify and sequence Brucella omp2a as a DIVA solution and tRNA (uracil-5-)-methyltransferase as a species marker in the serum samples to determine the etiological agent involved in brucellosis field cases. Using this method, we identified the involvement of both the Rev. 1 vaccine strain and a field strain in an outbreak of brucellosis in a flock. This method represents a novel approach in studying the etiology of brucellosis using serum samples as a source of the pathogen’s DNA. Full article
Show Figures

Figure 1

20 pages, 410 KiB  
Review
Stenotrophomonas maltophilia and Its Ability to Form Biofilms
by Gina García, Jorge A. Girón, Jorge A. Yañez and María L. Cedillo
Microbiol. Res. 2023, 14(1), 1-20; https://doi.org/10.3390/microbiolres14010001 - 23 Dec 2022
Cited by 18 | Viewed by 6260
Abstract
In the last ten years, Stenotrophomonas maltophilia has gained increasing interest as an important agent of infection, which is why it has come to be recognized as a serious cause of nosocomial infections related to bloodstream infections, pneumonia, and cancer, mainly in patients [...] Read more.
In the last ten years, Stenotrophomonas maltophilia has gained increasing interest as an important agent of infection, which is why it has come to be recognized as a serious cause of nosocomial infections related to bloodstream infections, pneumonia, and cancer, mainly in patients with intensive care, and is associated with high mortality rates in immunocompromised patients, with prolonged hospital stays and extensive use of antimicrobials. The importance of this microorganism lies in its low pathogenicity, high multiresistance to various antibiotics, and frequent and persistent isolation in predisposed patients. In addition, few studies have evaluated its epidemiology and clinical relevance. The pathogenesis of biofilms lies mainly in the fact that they can generate persistent chronic infections that are difficult to eradicate. To this extent, it is important to make the characteristics of the biofilm formation behavior of Stenotrophomonas maltophilia known and generate more knowledge about its colonization or infection in humans through this review, which discusses more recent information. Full article
(This article belongs to the Special Issue Microbial Biofilms and Host Immune Response)